|
Author, year | Animal model | Dosage regimen | Findings |
|
Sugimoto et al., 2002 [8]
| TNBS colitis; C57BL/6 and BALB/c mice | Dietary; 0.5, 2.0, and 5.0% 7 days | Inhibits Th1 cytokine profile in CD4+ T cells by suppressing IL-12 production in macrophages; proposed mechanism: NF-κB downregulation |
|
Perkins et al., 2002 [9]
| Min/+ mice and wild-type C57Bl/6J mice | Dietary; 0.1%, 0.2%, and 0.5% 15 weeks or single dose intraperitoneal injection | Concluded curcumin useful in the chemoprevention of human intestinal malignancies related to Apc mutations (advantage over NSAIDS in is its ability to decrease intestinal bleeding linked to adenoma maturation) At 0.2 and 0.5%, it reduced adenoma multiplicity by 39 and 40%, respectively Hematocrit values in untreated mice were drastically reduced |
|
Perkins et al., 2003 [10]
| Apc (Min/+) mice | Dietary; 0.2% and or aspirin (0.05%)
| Aspirin and curcumin act during different “windows” of neoplastic development |
|
Ukil et al., 2003 [11] | TNBS colitis; BALB/c mice
| Dietary; 50, 100, and 300 mg/kg; 10 days before treatment and 8 days after induction | Significant reduction in neutrophil infiltration (decreased MPO activity), lipid peroxidation (decreased malondialdehyde activity), and decreased serine protease activity.; also reduction in IFN-, IL-12, iNOS mRNA expression, and NF-κB |
|
Salh et al., 2003 [12] | DNBS colitis; C3H mice
| Dietary; 0.25% 5 days before treatment and 5 days after induction | NF-κB inhibition; reduced MPO activity, IL-1β activity, and p38 MAPK activity Reduced weight loss, histological severity, and reduction in inflammatory markers |
|
Jian et al., 2005 [13] | TNBS colitis; SPF Wistar rats | Dietary; 2.0%, 14 days | NF-κB, IκB, IL-1, and IL-10 improved histological score, suppression of NF-κB, blockage of IκB degradation, suppression of IL-1, and increase IL-10 expression |
|
Jiang et al., 2006 [14] | TNBS colitis; Sprague-Dawley rats | 30 and 60 mg/kg day, intraperitoneal injection 14 days | Reduced MPO activity, decreased COX-2, IFN- and TNF-expression, and increased PGE2 expression |
|
Zhang et al., 2006 [15] | TNBS colitis; Sprague-Dawley rats | 30 mg/kg/day, intraperitoneal injection 15 days | Reduced myeloperoxidase (MPO) activity Decreased the expression of Th1 cytokines (IL-12, IFN-gamma, TNF-alpha, and IL-1) Increased the expression of Th2 cytokines (IL-4 and IL-10) Increased proportion of IFN-gamma/IL-4 in splenocytes and circulation Improved weight loss and histological images |
|
Venkataranganna et al., 2007 [16] | DNCB colitis; Wistar rats | Dietary; 25, 50, and 100 mg/kg 10 days | Down-regulation of iNOS and NF-κB expression Decrease in MPO, LPO, and ALP activities |
|
Camacho-Barquero et al., 2007 [17] | TNBS colitis | Dietary; 50–300 mg/kg 14 days | Reduced MPO activity and tumour necrosis factor alpha (TNF)-alpha Diminished p38 MAPK activity; decreases COX-2 and iNOS expression Reduced nitrites |
|
Martelli et al., 2007 [18] | DNBS colitis; BALB/c mice | Dietary; 45 mg/kg; ±capsazepine intraperitoneally, (30 min before curcumin) 7 days | Reduction in the activation of p38 MAPK Down-regulation of COX-2 and iNOS expression Reductions in MPO activity and (TNF)-alpha Reduced nitrites
|
|
Deguchi et al., 2007 [19] | DSS colitis; BALB/c mice | Dietary; 2.0% wt/wt 14 days | Reduced disease activity index, histological colitis score, and MPO activity Suppressed NF-κB activity |
|
Billerey-Larmonier et al., 2008 [20] | TNBS colitis; BALB/c and SJL/J mice | Dietary; 2.0% wt/wt 9 days | BALB/c mice: curcumin significantly increased survival, prevented weight loss, and normalized disease activity SJL/J mice: curcumin demonstrated no protective effects |
|
Larmonier et al., 2008 [21] | Specific pathogen-free wild-type 129/SvEv mice and IL-10 (−/−) mice | Dietary; 0.1–1% wt/wt 14 days | Reduced IFN-gamma and IL-12/23p40 in SPF mice (limited effects in IL-10 mice) Synergistic action of curcumin and IL-10 to inhibit NF-κB |
|
Nones et al., 2009 [22] | mdr1a −/− mice | Dietary; 0.2% 16–19 weeks | Upregulation of xenobiotic metabolism and a down-regulation of proinflammatory pathways (possibly mediated by pregnane X receptor (Pxr) and peroxisome proliferator-activated receptor alpha (PPARA) activation of retinoid X receptor (Rxr)) |
|
Lubbad et al., 2009 [23] | TNBS colitis Sprague-Dawley rats
| Dietary; 100 mg/kg 5 days | Reduced MPO and MDA concentrations in colitis models Diminished TLR-4, NF-κB, and MyD88 proteins in colitis models
|
|
Jia et al., 2011 [24] | DSS colitis; C57BL/6 mice | Dietary; 2% curcumin ± fish oil ± maize oil | Combined FO and curcumin suppressed NF-κB, in the colon mucosa |
|